Pre-Clinical Antitumor Activity of Gemcitabine-Cardiolipin Conjugate Presented at the American Association of Cancer Research Annual Meeting.
Business Wire › April 19, 2005
Linked as:
Extract
Pre-Clinical Antitumor Activity of Gemcitabine-Cardiolipin Conjugate Presented at the American Association of Cancer Research Annual Meeting.
LAKE FOREST, Ill. -- Evidence of Reduced Toxicity and Improved Efficacy Shown
E[acute accent]NeoPharm, Inc. (Nasdaq:NEOL) today presented pre-clinical data on the antitumor activity for its new drug candidate, gemcitabine-cardiolipin conjugate, at the annual meeting of the American Association of Cancer Research (AACR), April 16-20, 2005, in Anaheim, ...See the full content of this document
Sponsored links
